Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1315-1323

  Li, Ying Wei ^a   Zhu, Guo Yuan ^a   Shen, Xiao Ling ^a   Chu, Jian Hong ^a   Yu, Zhi Ling ^a   Fong, Wang Fun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

Author keywords

Breast cancer; EGFR; Furanodienone; HER2

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FURANODIENONE; GLYCOGEN SYNTHASE KINASE 3BETA; LIPOCORTIN 5; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CURCUMA PHAEOCAULIS; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; MEDICINAL PLANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHIZOME; STAINING; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; FURANS; HUMANS; RECEPTOR, ERBB-2; RNA, SMALL INTERFERING; SESQUITERPENES; SIGNAL TRANSDUCTION;

EID: 82455175221     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1624-x     Document Type: Article

References (31)

1. MF Press HJ Lenz 2007 EGFR, HER2 and VEGF pathways: validated targets for cancer treatment Drugs 67 14 2045 2075 17883287 10.2165/00003495-200767140- 00006 1:CAS:528:DC%2BD2sXhtleqsrrF (Pubitemid 47524565)
2. PM Harari 2004 Epidermal growth factor receptor inhibition strategies in oncology Endocr Relat Cancer 11 4 689 708 15613446 10.1677/erc.1.00600 1:CAS:528:DC%2BD2MXhtVarsb8%3D (Pubitemid 40065545)
3. DS Krause RA Van Etten 2005 Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2 172 187 16014887 10.1056/NEJMra044389 1:CAS:528:DC%2BD2MXmtFClsbs%3D (Pubitemid 41058349)
4. N Prenzel OM Fischer S Streit S Hart A Ullrich 2001 The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification Endocr Relat Cancer 8 1 11 31 11350724 10.1677/erc.0.0080011 1:CAS:528:DC%2BD3MXkvFegurg%3D (Pubitemid 32520251)
5. R Zandi AB Larsen P Andersen MT Stockhausen HS Poulsen 2007 Mechanisms for oncogenic activation of the epidermal growth factor receptor Cell Signal 19 10 2013 2023 17681753 10.1016/j.cellsig.2007.06.023 1:CAS:528: DC%2BD2sXovFylsLg%3D (Pubitemid 47353811)
6. MA Olayioye RM Neve HA Lane NE Hynes 2000 The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J 19 13 3159 3167 10880430 10.1093/emboj/19.13.3159 1:CAS:528:DC%2BD3cXlt1ajtLY%3D (Pubitemid 30428195)
7. LA Bazley WJ Gullick 2005 The epidermal growth factor receptor family Endocr Relat Cancer 12 Suppl 1 S17 S27 16113093 10.1677/erc.1.01032 1:CAS:528:DC%2BD2MXhtFyitb%2FK (Pubitemid 41395411)
8. Y Yarden 2001 The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities Eur J Cancer 37 Suppl 4 S3 S8 11597398 10.1016/S0959-8049(01)00230-1 1:CAS:528:DC%2BD3MXntlOku78%3D
9. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics, 2008 CA Cancer J Clin 58 2 71 96 18287387 10.3322/CA.2007.0010 (Pubitemid 351521864)
10. Nunes RA, Harris LN (2002) The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3(2):125-135 (discussion 136-127)
11. DM Abd El-Rehim SE Pinder CE Paish JA Bell RS Rampaul RW Blamey JF Robertson RI Nicholson IO Ellis 2004 Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma Br J Cancer 91 8 1532 1542 15480434 10.1038/sj.bjc.6602184 1:CAS:528:DC%2BD2cXotlCkurk%3D (Pubitemid 39486359)
12. G Hudelist CF Singer M Manavi K Pischinger E Kubista K Czerwenka 2003 Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors Breast Cancer Res Treat 80 3 353 361 14503808 10.1023/A:1024929522376 1:CAS:528: DC%2BD3sXlslOntr4%3D (Pubitemid 37046760)
13. C Bernard-Marty F Lebrun A Awada MJ Piccart 2006 Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions Drugs 66 12 1577 1591 16956305 10.2165/00003495-200666120-00004 1:CAS:528:DC%2BD28XhtFektrfF (Pubitemid 44373744)
14. M Scaltriti C Verma M Guzman J Jimenez JL Parra K Pedersen DJ Smith S Landolfi S Ramon y Cajal J Arribas J Baselga 2009 Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 28 6 803 814 19060928 10.1038/onc.2008.432 1:CAS:528:DC%2BD1cXhsVKlt77K
15. Y Yarden 2001 Biology of HER2 and its importance in breast cancer Oncology 61 Suppl 2 1 13 11694782 10.1159/000055396 1:CAS:528: DC%2BD3MXovFWjsLw%3D (Pubitemid 33033419)
16. J Carlsson H Nordgren J Sjostrom K Wester K Villman NO Bengtsson B Ostenstad H Lundqvist C Blomqvist 2004 HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review Br J Cancer 90 12 2344 2348 15150568 1:CAS:528:DC%2BD2cXks1aht7k%3D (Pubitemid 38961898)
17. S Menard SM Pupa M Campiglio E Tagliabue 2003 Biologic and therapeutic role of HER2 in cancer Oncogene 22 42 6570 6578 14528282 10.1038/sj.onc.1206779 1:CAS:528:DC%2BD3sXnsl2rsrc%3D (Pubitemid 37372337)
18. KL Jones AU Buzdar 2009 Evolving novel anti-HER2 strategies Lancet Oncol 10 12 1179 1187 19959074 10.1016/S1470-2045(09)70315-8 1:CAS:528: DC%2BD1MXhsV2lurrJ
19. AY Yip LA Tse EY Ong LW Chow 2010 Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review Anticancer Drugs 21 5 487 493 20220514 10.1097/CAD.0b013e3283388eaf 1:CAS:528:DC%2BC3cXks1Wktb4%3D
20. A Reid L Vidal H Shaw J de Bono 2007 Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu) Eur J Cancer 43 3 481 489 17208435 10.1016/j.ejca.2006.11. 007 1:CAS:528:DC%2BD2sXhsVSjsLc%3D (Pubitemid 46178540)
21. G Lurje HJ Lenz 2009 EGFR signaling and drug discovery Oncology 77 6 400 410 20130423 10.1159/000279388 1:CAS:528:DC%2BC3cXit1Ont70%3D
22. E Ma X Wang Y Li X Sun W Tai T Li T Guo 2008 Induction of apoptosis by furanodiene in HL60 leukemia cells through activation of TNFR1 signaling pathway Cancer Lett 271 1 158 166 18667267 10.1016/j.canlet.2008.06.008 1:CAS:528:DC%2BD1cXht1Sis7nF
23. H Makabe N Maru A Kuwabara T Kamo M Hirota 2006 Anti-inflammatory sesquiterpenes from Curcuma zedoaria Nat Prod Res 20 7 680 685 16901812 10.1080/14786410500462900 1:CAS:528:DC%2BD28XnslCitLg%3D (Pubitemid 43878619)
24. K Tanaka Y Kuba A Ina H Watanabe K Komatsu 2008 Prediction of cyclooxygenase inhibitory activity of curcuma rhizome from chromatograms by multivariate analysis Chem Pharm Bull (Tokyo) 56 7 936 940 10.1248/cpb.56.936 1:CAS:528:DC%2BD1cXhtFOmtLbL (Pubitemid 351949707)
25. W Wang S Yang Y Su Z Xiao C Wang X Li L Lin BM Fenton SF Paoni I Ding P Keng P Okunieff L Zhang 2007 Enhanced antitumor effect of combined triptolide and ionizing radiation Clin Cancer Res 13 16 4891 4899 17699869 10.1158/1078-0432.CCR-07-0416 1:CAS:528:DC%2BD2sXptVGmtLo%3D (Pubitemid 47294797)
26. M Ricote I Garcia-Tunon B Fraile C Fernandez P Aller R Paniagua M Royuela 2006 P38 MAPK protects against TNF-alpha-provoked apoptosis in LNCaP prostatic cancer cells Apoptosis 11 11 1969 1975 17031491 10.1007/s10495-006-0086-9 1:CAS:528:DC%2BD28XhtFKmtrrO (Pubitemid 44691580)
27. AK Tse CK Wan GY Zhu XL Shen HY Cheung M Yang WF Fong 2007 Magnolol suppresses NF-kappaB activation and NF-kappaB regulated gene expression through inhibition of IkappaB kinase activation Mol Immunol 44 10 2647 2658 17240450 10.1016/j.molimm.2006.12.004 1:CAS:528:DC%2BD2sXhvVSls7s%3D (Pubitemid 46240318)
28. D Zhang A Pal WG Bornmann F Yamasaki FJ Esteva GN Hortobagyi C Bartholomeusz NT Ueno 2008 Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells Mol Cancer Ther 7 7 1846 1850 18644997 10.1158/1535-7163.MCT-08-0168 1:CAS:528:DC%2BD1cXoslCgtLc%3D
29. YM Li Y Pan Y Wei X Cheng BP Zhou M Tan X Zhou W Xia GN Hortobagyi D Yu MC Hung 2004 Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis Cancer Cell 6 5 459 469 15542430 10.1016/j.ccr.2004.09.027 1:CAS:528:DC%2BD2cXhtVGlurvF (Pubitemid 39469982)
30. D Patel R Bassi A Hooper M Prewett DJ Hicklin X Kang 2009 Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation Int J Oncol 34 1 25 32 19082474 1:CAS:528:DC%2BD1MXht1CqsLo%3D
31. G Chiosis AB Keeton 2009 Assay for isolation of inhibitors of her2-kinase expression Methods Mol Biol 486 139 149 19347621 10.1007/978-1-60327-545-3-10 1:CAS:528:DC%2BD1MXmvVSqsrc%3D